Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Maprotiline”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 217 records · Page 12Linked to original sources
PubMed1981

Zimelidine vs maprotiline in depressed outpatients. A preliminary report.

Outpatients with endogenous depression diagnosed according to the research diagnostic criteria of Feighner et al. were randomly referred to treatment with zimelidine (100 mg b.i.d., group Z) or maprotiline (75 mg b.i.d., group M). Patients who did not respond to treatment by days 28 were crossed over to the other drug. This preliminary report comprises results up to day 28 and includes antidepressive effect as rated by CPRS and globally, side effects, clinical chemistry and ECG. Ratings were double-blind at days 0, 7, 14 and 28, and a washout period of 4--7 days preceeded the trial. Group Z includes 27 and group M 28 patients with equal distribution of sex, age, duration of present episode, initial severity, etiology and previous course. There were 11 dropouts in group M and 5 in group Z due to side effects or treatment failure. On the other hand, 8 patients in group Z had to cross over to the other drug versus 2 in group M. According to the total CPRS score and the global score the antidepressive effect was somewhat better in group Z at 2 weeks but similar at 1 and 4 weeks. Group Z is less sedative but still seems to have a better anti-anxiety effect. Side effects were on a low level. There was a greater number of patients in group Z who complained of nausea, vomiting, loose stools, sleep disorder and sweating, and in group M dry mouth, drowsiness, dizziness and accomodation difficulties. Chemical analyses and ECG showed slight and inconsistent changes.

Adult↗
PubMed1988

Sedative effects of maprotiline and amitriptyline.

By means of critical flicker fusion measurements and subjective estimation of drowsiness, experiments with 12 healthy subjects over periods of 8 h showed that maprotiline caused less than half the amount of sedation compared to amitriptyline, both drugs given in single doses of 50 mg. The experiments were blind, randomized and placebo controlled. Implications for clinical use are discussed.

Amitriptyline↗
PubMed1999

Acute toxicity profile of maprotiline in the rat.

The aim of the present study was to examine the toxic effects of single oral administrations of the antidepressant maprotiline at 150 mg/kg or 300 mg/kg using female Sprague-Dawley rats. Body-weight gain was significantly reduced in the group receiving 300 mg/kg on days 1-5 of the study (P<0.01). A significant reduction in food and water intake was observed on days 1 and 2 of the study (P<0.01) in the 300 mg/kg group and on day 1 in the 150 mg/kg group (P<0.05). There was a significant decrease in nocturnal home cage activity over the first five days of the study in the 300 mg/kg group (P<0.01). A significant hypothermic response was observed in both 150 and 300 mg/kg groups at 1, 2 and 4 hr after dosing (P<0.01), that had returned to control values within 8 hr following administration. This study demonstrates that a multi-parameter approach is appropriate for the investigation of high doses of antidepressants in rodents.

Animals↗
PubMed1979

Epileptiform seizures with maprotiline hydrochloride.

Two cases are described who developed epileptic seizures whilst taking maprotiline hydrochloride in therapeutic dosage. In both cases the electroencephalogram was normal and the fits stopped on withdrawal of the drug.

Adult↗
PubMed1980

MHPG as a predictor of antidepressant response to imipramine and maprotiline.

To explore the hypothesis that depressed patients with low pretreatment levels of urinary 3-methoxy-4-hydroxyphenylglycol (MHPG) respond more favorably to antidepressant drugs which act on noradrenergic neuronal systems than do patients with high MHPG levels, the authors administered 150--200 mg/day of imipramine or maprotiline to 13 depressed patients. All of the 5 patients with low pretreatment MHPG levels responded to treatment compared with 1 of the 14 patients with high MHPG levels; 4 patients dropped out of the study.

Adult↗
PubMed1977

Maprotiline (Ludiomil) in depression: a report of a monitored release study of 10,000 patients in general practice.

In a three-week study of 10,000 general practice patients with depressive illness, a single dose of maprotiline 75 mg at night was effective therapy in three-quarters of the patients who completed the study. At this dose the drug was well tolerated, and troublesome side-effects presented in only a small percentage of patients. Drowsiness was the most commonly reported side-effect, and the main reason for withdrawal of treatment. The drug was acceptable to most physicians, and in this study was used in a wide range of patients and over a broad spectrum of depressive illness.

Adjustment Disorders↗
PubMed1988

Case report of hepatotoxicity associated with maprotiline.

A patient with unipolar affective disorder developed elevations in her liver enzymes shortly after initiation of therapy with maprotiline. The enzyme levels rapidly returned to normal after cessation of the drug with no residual liver disease.

Anthracenes↗
PubMed1994

Effects of hypericum extract LI 160 compared with maprotiline on resting EEG and evoked potentials in 24 volunteers.

In a randomized double-blind study, the effect of hypericum extract was compared to that of maprotiline in 24 healthy volunteers. The investigations included measurements of resting EEG as well as visual and acoustic evoked potentials. In resting EEGs, both medications revealed oppositely directed changes in the theta frequencies, and mainly similarly directed changes in alpha and beta frequencies. Measurements of evoked potentials in the theta and beta frequencies supported these results. The results indicate improved cognitive functions mainly with the treatment of hypericum extract.

Adolescent↗
PubMed1980

Comparison of the efficacy of sustained-release amitriptyline with maprotiline in the treatment of depressive illness.

Forty consecutive psychiatric patients referred to hospital with a diagnosis of depressive illness were randomly allocated to double-blind treatment with either 50 mg sustained-release amitriptyline or 75 mg maprotiline in night-time dosage. The dosage was doubled after 1 week. Rating scale assessments were carried out regularly over a 5-week period. The results indicated that there was a significant improvement with both drugs which occurred at approximately the same speed and to the same extent. Side-effects were complained of by approximately as many patients on both forms of treatment.

Adult↗
PubMed1999

[Extensive eosinophilic pulmonary infiltrates in a depressive patient treated with maprotiline].

A 74 year old man developed progressive dyspnea under treatment with the tetracyclic antidepressant maprotiline for three months. A chest x-ray revealed extended pulmonary infiltrates. Marked eosinophilia of the periperal blood was found (up to 2300/microliter). Rapid clinical and radiological improvement was observed solely by withholding the drug. The eosinophil count retourned to normal within a few weeks. The possible pathogenesis is discussed and the literature reviewed.

Aged↗
PubMed2002

[Comparative study of electro-acupuncture and maprotiline in treating depression].

OBJECTIVE: To compare the effect of electro-acupuncture (EA) and maprotiline (Map) in treating depression. METHODS: Thirty patients of depression were treated with EA and 31 patients with Map orally taken respectively. The therapeutic effect and side-effect were evaluated by measurement of Hamilton Depression Rating Scale (HAMD), Self-Rating Scale for Depression (SDS), Self-Rating Scale for Anxiety (SAS), Clinical Global Impression Scale (CGI) and Asberg Rating Scale for side-effects (ARS) before treatment and on the day 14, 28 and 42 of the therapeutic course. RESULTS: After treatment, the scores of HAMD and SDS lowered significantly (P < 0.01) than before treatment, and with insignificant difference between the group (P > 0.05). For patients with somatic syndrome, the HAMD score decrease rate was obviously higher in the Map group than that in the EA group. However, for the patients with anxiety somatization syndrome, the score of SAS, ARS in the EA group were significantly lower than those in the Map group (P < 0.05). Moreover, the efficacy index was higher in the EA group (P < 0.01). CONCLUSION: Both EA and Map are effective in treating depression.

Acupuncture Therapy↗
PubMedDate not supplied

[Suicide with chloroquine combined with maprotiline and trimipramine].

Report on suicide with chloroquine in combination with maprotiline and trimipramine. Chloroquine and his metabolite monodesethylchloroquine could be determined in organs and body fluids. The highest organ-concentrations of chloroquine were found in liver and kidney. The survival time and dose are discussed.

Chloroquine↗
PubMed2004

[Comparative observation on efficacy of jieyu pill and maprotiline in treating depression].

OBJECTIVE: To investigate the clinical efficacy, adverse reaction and safety of Jieyu pill (JYP) in treating depression. METHODS: The randomized controlled trial was conducted in 28 patients in the treated group and 29 patients in the control group treated with maprotiline (Map). The efficacy of treatment was evaluated before treatment and 14, 28 and 42 days after treatment, with Hamilton depression rating scale (HAMD), self-rating scale for depression (SDS), self-rating scale for anxiety (SAS) and clinical global impression (CGI), the adverse reaction was assessed by Asberg Rating Scale (ARS). RESULTS: JYP was effective in treating depression, the markedly effective rate being 78.8%, corresponded to that of Map (82.8%, P > 0.05). After treatment, the scores assessed by HAMD, SDS and SAS were all lower than those before treatment (P < 0.01) respectively, but comparison between the two groups showed insignificant difference (P > 0.05). However, scores of ARS were significantly lower in the treated group than that in the control group, and the efficacy index of JYP was significantly higher than that of Map (P < 0.01). CONCLUSION: JYP in treating depression shows the efficacy corresponded to that of Map and with less adverse reaction.

Adolescent↗
PubMedDate not supplied

Comparative sorption of clomipramine, viloxazine, and maprotiline hydrochlorides in polyvinylchloride bags and glass vials.

The sorption of clomipramine, viloxazine, and maprotiline hydrochlorides was studied comparatively in polyvinylchloride (PVC) bags and glass flasks for up to 72 hours. When stored in glass flasks, no decrease in concentration was observed for any of the three drugs, either in dextrose or sodium chloride isotonic solution. When stored in PVC bags, a slight loss (about 7% within 72 hours), was noted for clomipramine hydrochloride in both isotonic solutions, but not for the other two drugs.

Clomipramine↗
PubMed1991

[Ichthyosis and alopecia after maprotiline: corneolysis caused by temporary disorder of keratinization].

A 37-year-old woman developed ichthyosiform desquamation of the skin and a severe diffuse alopoecia 3 weeks after taking the antidepressant maprotilin. No signs of inflammation were present. Histology revealed acanthosis with preserved stratum granulosum, follicular hyperkeratosis and dystrophic changes of the hair follicle. Electron microscopy revealed rarefication of tonofilaments and necrobiotic changes of epidermal keratinocytes with vacuolar degeneration of the cytoplasm and disorganization of the organelles. Pathogenetically this disease represents a drug-induced transitory disorder to keratinization, which had resulted in desquamation of the stratum corneum and alopecia. The authors propose the designation corneolysis for this pathogenetic principle.

Adjustment Disorders↗
PubMed1990

[Maprotiline poisoning in an eleven-month-old infant].

The authors report the case of an eleven-month old infant who was given maprotiline and clobazam. He was found in coma state and suffered from convulsions, that were treated with phenobarbital. The electrocardiogram showed a right bundle branch block and a left anterior hemiblock over 72 h. The child then recovered without sequelae.

Anthracenes↗
PubMedDate not supplied

[The Stevens-Johnson syndrome from maprotiline and propranolol?].

A wide variety of agents have been associated with erythema multiforme, particularly drugs and infectious agents. We describe a typical Stevens-Johnson's syndrome developing 15 days after initiation of propranolol and maprotiline therapy. Other etiologies have been excluded by appropriate investigations and the responsibility of each drug is discussed.

Adult↗
PubMed1989

[Psychometric findings in treatment using the selective MAO-A inhibitors moclobemide and maprotiline].

Two groups of depressed patients were treated either with a selective MAO-A-inhibitor, moclobemide (n = 13), or a tetracyclic antidepressant, maprotiline (n = 18), in a 28 days lasting investigation. Before and after treatment psychopathologic symptoms were rated using Hamilton Depression Scale, motor performance were proven by the Motorische Leistungs-Serie (MLS), and acoustic and visual sensorimotor performance were investigated using Bettendorff Reaktiometer T96. Deterioration of psychomotor performance were seen in patients without amelioration of their psychopathologic symptoms, especially when treated with moclobemide. These findings were regarded as a hint that possibly the therapeutic agent interacts with the wrong transmitter system and perhaps this is the reason for the deterioration of psychomotor functions.

Adult↗